XTX Topco Ltd Raises Stake in Twist Bioscience Co. (NASDAQ:TWST)

XTX Topco Ltd boosted its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 128.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,446 shares of the company's stock after purchasing an additional 19,928 shares during the period. XTX Topco Ltd owned approximately 0.06% of Twist Bioscience worth $1,647,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of TWST. Vanguard Group Inc. increased its position in shares of Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after purchasing an additional 189,791 shares during the last quarter. ARK Investment Management LLC increased its position in shares of Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after acquiring an additional 237,772 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after acquiring an additional 532,040 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Twist Bioscience by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock worth $63,895,000 after acquiring an additional 6,908 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Twist Bioscience by 63.5% during the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock worth $35,148,000 after purchasing an additional 293,751 shares during the period.

Insider Activity

In other news, SVP Paula Green sold 1,259 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $62,131.65. Following the completion of the transaction, the senior vice president now owns 132,014 shares in the company, valued at approximately $6,514,890.90. This represents a 0.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 1,726 shares of Twist Bioscience stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total transaction of $71,939.68. Following the sale, the chief executive officer now owns 660,966 shares in the company, valued at $27,549,062.88. This represents a 0.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,796 shares of company stock worth $1,077,383. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Stock Down 4.3 %

NASDAQ:TWST traded down $1.65 during mid-day trading on Friday, hitting $36.80. The stock had a trading volume of 747,299 shares, compared to its average volume of 983,176. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.96 and a twelve month high of $60.90. The company has a market capitalization of $2.20 billion, a PE ratio of -10.89 and a beta of 2.34. The stock has a 50-day simple moving average of $40.57 and a two-hundred day simple moving average of $44.44.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company's revenue was up 24.1% on a year-over-year basis. During the same period last year, the business earned ($0.75) EPS. On average, equities research analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Barclays cut their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Robert W. Baird raised their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Guggenheim set a $50.00 price objective on shares of Twist Bioscience in a research note on Friday, March 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $52.80.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.